Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Examining the impacts of pharmacist authority to administer drugs by injection on timely denosumab dosing
EF 2023-24
Résumé
Denosumab is an injection given every six months to prevent fractures in men and women with osteoporosis. However, delaying or stopping denosumab therapy can increase the risk of vertebral fractures. Only doctors or nurses could administer denosumab until recently, so patients typically had to bring the drug after picking it up at the pharmacy. We found that many patients delayed or missed denosumab injections, despite the potential worsening of health and fracture risks. Due to the COVID-19 pandemic, we saw a drop in patients receiving denosumab therapy on time with shifts to virtual care and disruptions to healthcare services. Pharmacists, who are easily accessible, have the potential to improve timely administration of denosumab. Yet their authority to administer drugs by injections (AADI), including denosumab, varies across Canada: pharmacists in Alberta have had unrestricted AADI, whereas in Ontario, AADI applied only for education purposes until July 2023. My research will compare the proportion of patients who receive denosumab on time by province over time, and examine the benefit of pharmacist AADI on timely denosumab administration during the pandemic. Pharmacist AADI can enable patients to receive denosumab at the pharmacy when picking up their drug. Better on-time denosumab therapy with pharmacist AADI will lessen health and economic consequences (e.g. pain, disability, early deaths) associated with fractures due to osteoporosis.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505939
Name
Choi Yuna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining the impacts of pharmacist authority to administer drugs by injection on timely denosumab dosing
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Safety And Effectiveness; Drug Utilization; Health Policy; Health Services; Osteoporosis; Pharmacoepidemiology; Pharmacy; Post-Market Surveillance; Real-World Studies
Abstract
Denosumab is an injection given every six months to prevent fractures in men and women with osteoporosis. However, delaying or stopping denosumab therapy can increase the risk of vertebral fractures. Only doctors or nurses could administer denosumab until recently, so patients typically had to bring the drug after picking it up at the pharmacy. We found that many patients delayed or missed denosumab injections, despite the potential worsening of health and fracture risks. Due to the COVID-19 pandemic, we saw a drop in patients receiving denosumab therapy on time with shifts to virtual care and disruptions to healthcare services. Pharmacists, who are easily accessible, have the potential to improve timely administration of denosumab. Yet their authority to administer drugs by injections (AADI), including denosumab, varies across Canada: pharmacists in Alberta have had unrestricted AADI, whereas in Ontario, AADI applied only for education purposes until July 2023. My research will compare the proportion of patients who receive denosumab on time by province over time, and examine the benefit of pharmacist AADI on timely denosumab administration during the pandemic. Pharmacist AADI can enable patients to receive denosumab at the pharmacy when picking up their drug. Better on-time denosumab therapy with pharmacist AADI will lessen health and economic consequences (e.g. pain, disability, early deaths) associated with fractures due to osteoporosis.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Choi, Yuna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~